What are the extrapyramidal side effects of haloperidol (Haldol) and how should they be monitored and managed?

Extrapyramidal Effects of Haloperidol

Haloperidol, as a high-potency typical antipsychotic, frequently causes extrapyramidal side effects (EPS) including acute dystonia, parkinsonism, akathisia, and tardive dyskinesia, which require vigilant monitoring and prompt management to prevent serious morbidity and medication non-compliance. 1, 2

Types of Extrapyramidal Side Effects

Acute EPS (occur early in treatment)

Dystonia:

• Sudden spastic muscle contractions affecting neck, eyes (oculogyric crisis), or torso 1, 3
• Risk factors: young age, male gender, high-potency agents 1
• Life-threatening presentation: laryngospasm causing choking, difficulty breathing, or stridor 3
• Treatment: Responds well to anticholinergic medications (benztropine) or antihistamines (diphenhydramine) 1, 2
• Typically occurs after first few doses or dose increases 3

Drug-Induced Parkinsonism:

• Bradykinesia, tremors, and rigidity 1
• Treatment: Anticholinergic agents or dopaminergic agonists (amantadine) 1, 3
• Clinical pitfall: Can be difficult to differentiate from negative symptoms of psychosis or catatonia 1

Akathisia:

• Severe subjective restlessness with pacing or physical agitation 1
• Common pitfall: Frequently misinterpreted as psychotic agitation or anxiety, leading to inappropriate dose increases 1
• Major cause of medication non-compliance 1
• Treatment approach:
  • First-line: Lower haloperidol dose if clinically feasible 1
  • Antiparkinsonian agents often ineffective 1
  • Consider β-blockers (propranolol 10-30 mg 2-3 times daily) or benzodiazepines (lorazepam) 1, 4, 5
  • Switch to quetiapine or olanzapine if persistent 4

Tardive Dyskinesia (late-onset, potentially irreversible)

• Involuntary rhythmical movements of tongue, face, mouth, jaw, and potentially extremities 1, 2
• Incidence: Up to 50% of youth receiving neuroleptics may experience some form of tardive or withdrawal dyskinesia 1
• Risk factors: Long-term use, elderly patients, high doses, female gender 1, 2
• Early warning sign: Fine vermicular tongue movements 2
• Critical point: May be irreversible even after medication discontinuation 1, 2

Monitoring Protocol

Before initiating haloperidol:

• Baseline assessment using Abnormal Involuntary Movement Scale (AIMS) 1
• Document any pre-existing movement abnormalities 1

During treatment:

• Children and adolescents are at HIGHER risk for EPS than adults 1
• Monitor for dyskinesias every 3-6 months using AIMS 1
• Weekly monitoring initially to establish rapport and ensure compliance 1
• Assess for EPS at each visit, particularly during dose adjustments 1, 2

Management Strategies

Prophylactic Approach:

• Consider prophylactic antiparkinsonian agents for patients at high risk for acute dystonia (young males, history of dystonic reactions) 1
• Particularly important for patients with compliance concerns (paranoid patients who distrust medications) 1
• Re-evaluate need after acute phase as many patients no longer require prophylaxis during long-term therapy 1

When EPS Develops:

• For acute dystonia/parkinsonism: Anticholinergic medications are effective, more so when given after symptoms develop rather than prophylactically 5
• For akathisia: Lorazepam controlled symptoms in 14 of 16 patients, while prophylactic antiparkinsonians were ineffective 5
• Combination therapy: IV haloperidol plus benzodiazepines produces significantly less EPS (p<0.001) than haloperidol alone 6

When Tardive Dyskinesia Occurs:

• No specific effective treatment exists 1
• Continue current dose only if patient is in full remission and dose change would precipitate relapse 1
• Otherwise, attempt to lower dose or switch to atypical antipsychotic 1
• Critical decision point: Risk-benefit must be carefully weighed as discontinuation may unmask or worsen symptoms temporarily 1, 2

Special Considerations

Dosing to minimize EPS:

• Use lowest effective dose 1
• Recent evidence suggests low-dose injectable haloperidol (≤0.5 mg) may be as effective as higher doses with potentially better outcomes 7
• Intramuscular dosing preferred over IV in emergency settings due to FDA warnings about deaths with high-dose IV administration 3

Drug interactions:

• Anticholinergic medications used to treat EPS may worsen anticholinergic delirium 8
• Rifampin decreases haloperidol levels by 70%, potentially necessitating dose adjustments 2

Withdrawal considerations:

• Gradual withdrawal may reduce withdrawal-emergent neurological signs 2
• Antiparkinsonian agents may need to continue after haloperidol discontinuation due to different excretion rates 2